Drug Profile
Research programme: hepatitis C polymerase inhibitors - Vaxart
Latest Information Update: 16 Feb 2018
Price :
$50
*
At a glance
- Originator Biota Holdings
- Developer Aviragen Therapeutics
- Class
- Mechanism of Action Polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 13 Feb 2018 Aviragen Therapeutics has merged with Vaxart forming Vaxart
- 16 Jul 2016 No recent reports of development identified for preclinical development in Hepatitis-C in Australia
- 12 Apr 2016 Biota Pharmaceuticals is now called Aviragen Therapeutics